Celcuity Inc. (NASDAQ:CELC) Receives Average Rating of “Buy” from Analysts

Shares of Celcuity Inc. (NASDAQ:CELC) have been given an average rating of “Buy” by the seven research firms that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $30.17.

CELC has been the topic of several research reports. Needham & Company LLC boosted their price objective on shares of Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Celcuity in a report on Friday, November 15th.

Celcuity Trading Down 2.7 %

Shares of Celcuity stock opened at $12.25 on Friday. The company has a market cap of $454.84 million, a price-to-earnings ratio of -4.69 and a beta of 0.73. Celcuity has a 1 year low of $10.35 and a 1 year high of $22.19. The company’s fifty day simple moving average is $12.31 and its 200-day simple moving average is $14.45. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65.

Institutional Investors Weigh In On Celcuity

Several large investors have recently modified their holdings of CELC. State Street Corp boosted its stake in Celcuity by 152.2% in the 3rd quarter. State Street Corp now owns 1,107,415 shares of the company’s stock valued at $16,512,000 after buying an additional 668,318 shares in the last quarter. Braidwell LP boosted its position in Celcuity by 71.2% in the third quarter. Braidwell LP now owns 884,306 shares of the company’s stock valued at $13,185,000 after buying an additional 367,663 shares in the last quarter. Candriam S.C.A. acquired a new stake in shares of Celcuity during the fourth quarter worth approximately $3,450,000. Charles Schwab Investment Management Inc. raised its stake in shares of Celcuity by 226.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 221,671 shares of the company’s stock valued at $3,305,000 after acquiring an additional 153,712 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Celcuity by 27.6% in the 3rd quarter. Geode Capital Management LLC now owns 630,369 shares of the company’s stock worth $9,401,000 after acquiring an additional 136,518 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.